Shares of TransMedics Group, Inc. (NASDAQ: TMDX) are surging 13.28% in pre-market trading on Thursday, following the release of the company's impressive second-quarter 2025 financial results. The medical technology company, which specializes in organ transplant solutions, not only beat analyst expectations but also raised its full-year revenue guidance, signaling strong confidence in its growth trajectory.

TransMedics reported quarterly earnings of $0.92 per share, significantly outperforming the analyst consensus estimate of $0.44 by 111.01%. This represents a substantial 162.86% increase from the $0.35 per share reported in the same period last year. The company's total revenue for Q2 reached $157.4 million, marking a 38% year-over-year increase and surpassing the expected $147.9 million. Net income for the quarter stood at a robust $34.9 million.

In light of these strong results, TransMedics raised its full-year 2025 revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year. The company's president and CEO, Waleed Hassanein, expressed confidence in their strategy and emphasized their focus on achieving 10,000 US National OCS Program (NOP) transplants by 2028. Additionally, TransMedics reported progress in its technology development, including receiving conditional Investigations Device Exemption (IDE) approval from the FDA for its Next-Gen OCS™ Lung trial and launching the OCS NOP digital ecosystem, NOP ACCESS™, across major transplant programs in the United States. These developments, coupled with the strong financial performance, appear to have fueled investor optimism, driving the stock's pre-market rally.